29th January – 1st February 2018 | Paris, France

REGISTER NOW 

guide-red agenda-dark speakers-blue

 

Post-Conference Focus Day:

Microbiome for Immuno-Oncology

Thursday, 1st February

In recent years, researchers have been studying the pathogenesis of disease through the context of the human microbiome. With the microbiome’s impact on fundamental cell processes including metabolism and host immune response, modulation of microbiota as well microbiotaderived by products may influence the formation, progression and prevention of cancer.

This new evidence has sparked novel data that shows interindividual differences in the microbiome may account in varying therapeutic response rates to immune-modulating therapies. The purpose of this day will be to share cutting-edge research that promotes beneficial immune responses through gut microbiome modulation that enhance the clinical response for patients treated with IO therapeutics.

register-blue

Speakers include: 

Post Conference Focus Day - Speakers

 8.30 Morning Coffee and Registration

 9.30 Chair’s Opening Remarks

Laurence

9.40 The Impact of the Intestinal Microbiota in Therapeutic Responses Against Cancer

  • Exploring the influence of the human microbiome in anticancer immune responses
  • Suggesting mechanisms of microbial mediated effects in affecting anticancer
    immuno surveillance and translating into clinical reality
  • Harnessing new research to pave the way for more effective therapies and prophylactics

 10.25 Panel Presentation

 11.10 Morning Refreshments

 Assaf

11.40 A Novel RNA Expression Based Platform for Discovery of Microbiome Modulators to Improve Response to Checkpoint Inhibitors

  • BiomX novel discovery technology measures the direct dynamic response (RNA expression based) of the gut microbiome to checkpoint inhibitor administration
  • Providing a comprehensive approach for modulating the microbiome to improve checkpoint inhibitor response, through adding or eradicating bacteria using phage
  • Utilization of phage, either native or synthetically modified, to eradicate specific bacteria impacting response rate provides a promising novel therapeutic approach
  • Exploring the influence of the human microbiome in anticancer immune responses
 Arpita

12.10 Using the Microbiome to Create New Paradigms of Treatment in Oncology

  • The microbiome and checkpoint inhibitor therapies
  • Using insights in the microbiome to control efficacy, tolerability and safety of cancer immunotherapeutics
  • An experimental strategy to combine clinical study selections with microbiome profiling, host profiling and bioinformatics

 12.40 Roundtable Discussion

 13.10 End of Post Conference Focus Day